Description: Separating incident and prevalent populations is useful, but the use of a cohort to make an RTM adjustment is unwarranted in the population-based pre- versus post-period design. From Financing Chronic Care Monograph, M-HB05-1.

Description: Most health care delivered in the United States is based on the acute care model: it is episodic has a beginning, middle and end usually the patient recovers and interventions are designed to target a specific pathophysiologic abnormality. Chronic disease care, in contrast, often has no clear beginning and no end the focus is on managing over the long term with prevention of progression and complications. Further, many chronic diseases “travel together” comorbidities: for example, diabetes, hypertension, coronary artery disease CAD, heart failure, cerebrovascular disease, peripheral arterial disease and renal dysfunction are often found together.

Description: This paper presents a different approach to measuring Health Expectancy, especially as it relates to the elderly population. This new actuarial approach is described and numerous examples are given.

Description: Yi-Ling Lin, FSA, MAAA, FCA, started the SOA’s Predictive Analytics Certificate Program to keep pace with the impact big data and predictive modeling is having on the health care industry

Description: This is the abstract to the paper, A Comparative Analysis of Chronic and Non-Chronic Insured Commercial Member Cost Trends.

Description: Discussion of “Health Expectancy” paper and reply from author, Faye Albert. Discussion of Human Behavior: An Impediment to Future Mortality and Discussion of Health, Wealth and Wisdom - Living Long, Living Well: An Actuary Muses on Longevity

Description: A study of disability experience examines cost burden and degree of disability, and how these measures vary across different subpopulations.

Description: The presenters will focus on best practices in drug claim management in North America. The presentation is geared toward Canadian practice and insights, but is useful for practitioners in the U.S. and elsewhere, as well.

Description: The coming wave of biosimilars could dramatically affect prescription drug costs and benefit strategies over the next several years. The launch of many Humira biosimilars in 2023 is the Big Event that will largely determine the impact of the biosimilar wave. Payers have many decisions to make about coverage and formulary tiers. What factors will drive payer decision-making?

Description: This article discusses a study of the impact of the drug infliximab on Crohn's disease patients. This study had been approved in response to an SOA request for proposals for research on the health cost and utilization effects of a specific prescription drug.